Molecular serum portraits in patients with primary breast cancer predict the development of distant metastases

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 34, 2011, Pages 14252-14257

  Carlsson, Anders ^a   Wingren, Christer ^a   Kristensson, Malin ^a   Rose, Carsten ^a,b   Fernö, Mårten ^b   Olsson, Håkan ^b   Jernström, Helena ^b   Ek, Sara ^a   Gustavsson, Elin ^a   Ingvar, Christian ^a   Ohlsson, Mattias ^a   Peterson, Carsten ^a   Borrebaeck, Carl A K ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Affinity proteomics; Malignancy; Monitoring disease; Prognosis; Tumour relaps

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; BETA GALACTOSIDASE; BIOLOGICAL MARKER; CD40 ANTIGEN; CD40 LIGAND; COMPLEMENT COMPONENT C1S INHIBITOR; CUTANEOUS T CELL ATTRACTING CHEMOKINE; DIGOXIN; EOTAXIN; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1ALPHA; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 7; PLASMA PROTEIN; RANTES;

AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; BREAST CANCER; CANCER RECURRENCE; CANCER SIZE; CONTROLLED STUDY; DISTANT METASTASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; RECEIVER OPERATING CHARACTERISTIC; RISK ASSESSMENT;

ALGORITHMS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; DEMOGRAPHY; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; RECURRENCE; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; RISK FACTORS; TUMOR MARKERS, BIOLOGICAL;

EID: 80052142418     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1103125108     Document Type: Article

References (40)

1. Jemal A, et al. (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225-249.
2. La Vecchia C, et al. (2010) Cancer mortality in Europe, 2000-2004, and an overview of trends since 1975. Ann Oncol 21:1323-1360.
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717.
4. Dowsett M, et al. (2010) Meta-analysis of breast cancer outcomes in adjuvant trials of aromatase inhibitors versus tamoxifen. J Clin Oncol 28:509-518.
5. Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN (2007) Overview of resistance to systemic therapy in patients with breast cancer. Adv Exp Med Biol 608: 1-22.
6. Eifel P, et al. (2001) National Institutes of Health Consensus Development Conference Statement: Adjuvant therapy for breast cancer, November 1-3, 2000. J Natl Cancer Inst 93:979-989.
7. Goldhirsch A, et al.; Panel members (2009) Thresholds for therapies: Highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009. Ann Oncol 20:1319-1329.
8. van 't Veer LJ, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415:530-536.
9. Paik S, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826. (Pubitemid 40051905)
10. Duffy MJ, Evoy D, McDermott EW (2010) CA 15-3: Uses and limitation as a biomarker for breast cancer. Clin Chim Acta 411:1869-1874.
11. Ingvarsson J, et al. (2008) Detection of pancreatic cancer using antibody microarraybased serum protein profiling. Proteomics 8:2211-2219. (Pubitemid 351898027)
12. Sanchez-Carbayo M, Socci ND, Lozano JJ, Haab BB, Cordon-Cardo C (2006) Profiling bladder cancer using targeted antibody arrays. Am J Pathol 168:93-103. (Pubitemid 43062562)
13. Ellmark P, et al. (2006) Identification of protein expression signatures associated with Helicobacter pylori infection and gastric adenocarcinoma using recombinant antibody microarrays. Mol Cell Proteomics 5:1638-1646. (Pubitemid 44480391)
14. Wingren C, Ingvarsson J, Dexlin L, Szul D, Borrebaeck CAK (2007) Design of recombinant antibody microarrays for complex proteome analysis: Choice of sample labeling-tag and solid support. Proteomics 7:3055-3065. (Pubitemid 47477950)
15. Carter HB, Pearson JD (1993) PSA velocity for the diagnosis of early prostate cancer. A new concept. Urol Clin North Am 20:665-670. (Pubitemid 24141159)
16. McShane LM, et al.; Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics (2005) REporting recommendations for tumor MARKer prognostic studies (REMARK). Nat Clin Pract Oncol 2:416-422.
17. Chechlinska M, Kowalewska M, Nowak R (2010) Systemic inflammation as a confounding factor in cancer biomarker discovery and validation. Nat Rev Cancer 10:2-3.
18. Carlsson A, et al. (2008) Serum proteome profiling of metastatic breast cancer using recombinant antibody microarrays. Eur J Cancer 44:472-480. (Pubitemid 351179627)
19. Edén P, Ritz C, Rose C, Fernö M, Peterson C (2004) "Good Old" clinical markers have similar power in breast cancer prognosis as microarray gene expression profilers. Eur J Cancer 40:1837-1841. (Pubitemid 39036757)
20. Niméus-Malmström E, et al. (2008) Gene expression profiling in primary breast cancer distinguishes patients developing local recurrence after breast-conservation surgery, with or without postoperative radiotherapy. Breast Cancer Res 10:R34.
21. Sharma P, et al. (2005) Early detection of breast cancer based on gene-expression patterns in peripheral blood cells. Breast Cancer Res 7:R634-R644.
22. Aebersold R, Mann M (2003) Mass spectrometry-based proteomics. Nature 422: 198-207. (Pubitemid 36362757)
23. Ekins RP (1998) Ligand assays: From electrophoresis to miniaturized microarrays. Clin Chem 44:2015-2030.
24. Zhu H, Snyder M (2003) Protein chip technology. Curr Opin Chem Biol 7:55-63. (Pubitemid 36126493)
25. Anderson NL, Anderson NG (2002) The human plasma proteome: History, character, and diagnostic prospects. Mol Cell Proteomics 1:845-867.
26. Borrebaeck CAK, Wingren C (2009) Design of high-density antibody microarrays for disease proteomics: Key technological issues. J Proteomics 72:928-935.
27. Storr SJ, et al. (2006) Use of autoantibodies in breast cancer screening and diagnosis. Expert Rev Anticancer Ther 6:1215-1223. (Pubitemid 44304689)
28. Steinhauer C, Wingren C, Hager AC, Borrebaeck CAK (2002) Single framework recombinant antibody fragments designed for protein chip applications. Biotechniques (Suppl):38-45. (Pubitemid 36008162)
29. Wingren C, et al. (2005) Microarrays based on affinity-tagged single-chain Fv antibodies: Sensitive detection of analyte in complex proteomes. Proteomics 5: 1281-1291.
30. Borrebaeck CAK, Wingren C (2007) High-throughput proteomics using antibody microarrays: An update. Expert Rev Mol Diagn 7:673-686. (Pubitemid 47547731)
31. Carlsson A, et al. (2010) Plasma proteome profiling reveals biomarker patterns associated with prognosis and therapy selection in glioblastoma multiforme patients. Proteomics Clin Appl 4:591-602.
32. Cohen T, Nahari D, Cerem LW, Neufeld G, Levi BZ (1996) Interleukin 6 induces the expression of vascular endothelial growth factor. J Biol Chem 271:736-741. (Pubitemid 26034921)
33. Ravishankaran P, Karunanithi R (2011) Clinical significance of preoperative serum interleukin-6 and C-reactive protein level in breast cancer patients. World J Surg Oncol 9:18.
34. Xie K (2001) Interleukin-8 and human cancer biology. Cytokine Growth Factor Rev 12: 375-391.
35. Metwally FM, El-Mezayen HA, Ahmed HH (2010) Significance of vascular endothelial growth factor, interleukin-18 and nitric oxide in patients with breast cancer: Correlation with carbohydrate antigen 15.3. Med Oncol, in press.
36. Li J, et al. (2010) Role for ezrin in breast cancer cell chemotaxis to CCL5. Oncol Rep 24: 965-971.
37. Soria G, et al. (2011) Inflammatory mediators in breast cancer: Coordinated expression of TNFα & IL-1β with CCL2 & CCL5 and effects on epithelial-to-mesenchymal transition. BMC Cancer 11:130.
38. Drabsch Y, Ten Dijke P (2011) TGF-beta signaling in breast cancer cell invasion and bone metastasis. J Mammary Gland Biol Neoplasia 16:97-108.
39. Li J, Zhu H, Chen T, Dai G, Zou L (2011) TGF-beta1 and BRCA2 expression are associated with clinical factors in breast cancer. Cell Biochem Biophys 60:245-248.
40. Jeschke U, et al. (2005) Expression of sialyl Lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: Immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis. Anticancer Res 25(3A):1615-1622. (Pubitemid 40896773)